Get started
Work

A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's disease: Recommendations of the ISCTM Working Group

Year: 2020
Type: review
Abstract: Dementia is characterized by a significant decline in one of several cognitive domains such as memory, language and executive function, affecting independence and representing a significant deterioration from a previous level of functioning (1). Alzheimer’s Disease (AD) represents the most common form of dementia and contributes up to 70% of the almost 50 million dementia cases worldwide, a number that is projected to double in 20 years (2).
DOI: 10.14283/jpad.2020.37
Authors: Cedric O'Gorman, R. Khoury, A. Anderson, M. Carter, F. DiCesare, S. Dubé, L. Ereshefsky, G. Grossberg, N. Hefting, S. Khan, S. Lind, H. Moebius, T. Shiovitz, P. Rosenberg
Institutions: Axsome Therapeutics (United States), Saint Louis University, University of California, Los Angeles, Pfizer (United States), Avanir Pharmaceuticals (United States), Lundbeck (Denmark), Johns Hopkins University, Johns Hopkins Medicine
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,990
OpenAlex ID: W3037379701
FWCI: 0.207
Cites: 69
Cited by: 7
Related to: 10